Intercept Patent-Cliff Exposure & CMS Drug Spending Portfolio
Intercept (US): 2 reconciled FDA prescription therapies, $208.1M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2033-01-01 |
| 2024 CMS Total Public Spend | $208.1M |
| 2024 Medicare Part D Spend | $185.0M |
| 2024 Medicaid Spend | $23.1M |
| California HCAI SB 17 Filings | 8 WAC filings (max 25.8% 2-yr change) |